However, macrophage-induced T-cell suppression within the tumor microenvironment can diminish the therapeutic impact of osimertinib, while the establishment of an immunosuppressive TME facilitates the development of resistance to EGFR-TKIs [83]. This evidence concerns the gene EGFR and neoplasm.